An interventional study of Thor laser atherectomy in Peripheral Artery Disease, Peripheral Artery Stenosis and Peripheral Artery Calcification, sponsored by Philips Clinical & Medical Affairs Global. Recruiting at 29 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Peripheral Arterial Disease by Philips — 1 open to participants now, 1 under way, none of them phase 3. Peripheral Arterial Disease · Philips.
Among the 24 studies in Peripheral Arterial Disease by Philips, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 24th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →1 of the 24 studies in Peripheral Arterial Disease by Philips is open now, in 1 country.
By country, each count listing its studies:
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 155 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 142 across the 18 interventional studies, 70 across the 6 observational. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Philips Clinical & Medical Affairs Global, one of the names counted as Philips. Under that name alone:
Philips Clinical & Medical Affairs Global is the lead sponsor of 86 studies on the registry; 25 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 13 (81%) have results posted.
1 of the studies in Peripheral Arterial Disease by Philips that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Peripheral Arterial Disease by Philips, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD).
The main question[s] it aims to answer are:
Participants will:
Up to 30 sites in the U.S. will be selected to do this study.
Patients with pain in their legs when walking and/or resting that is due to lack of blood flow to their legs may be able to join the study. To join the study patients must also have blockages in their leg arteries that meet the study criteria.
Before the Thor procedure, patients will have a screening visit that includes a review of their medical records, questions about their medical history and medications taken for blood thinning or circulation, a physical examination of their legs, a test to check the blood flow in their legs (by checking arm and leg blood pressures), blood tests, and a pregnancy test if they are a female able to have children. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.
All patients in the study will have treatment with the Thor system. There is no "control group" (a group of patients that receives only standard treatment or receives no treatment at all) in this study. During the procedure, the doctor will take x-ray pictures of the leg arteries. They may also use other treatments such as angioplasty balloons, drug-coated balloons, stents, and filters that collect blood clots, if needed.
Patients treated with the Thor system will be watched until they are ready to go home or up to 24 hours after the procedure if they do not go home right away. Before they go home they will have a test to check the blood flow to their legs (by checking arm and leg blood pressures) and be checked for any adverse events.
Patients will return for visits at 30 days, 6 months, and 12 months after the Thor procedure. At these visits patients will be asked questions about their medical history and medications taken for blood thinning or circulation, have a physical examination of their legs, have a test to check the blood flow in their treated leg (by checking arm and leg blood pressures), have an ultrasound of their treated leg, and be checked for any adverse events. Patients will also answer questions about any trouble they have had with walking in the last week and their overall quality of life.
It will take up to 24 months (2 years) to enroll all of the patients in the study. Patients who join the study will be in the study for about 12 months (1 year) and will have all of the visits with their doctor that they would normally have for their PAD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic Inclusion Criteria:
Exclusion Criteria:
Angiographic Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with the Thor system
Device: Thor laser atherectomy
Treatment of de novo calcified lesions with laser atherectomy and calcium modification using the Thor system
Also known as: Thor calcium modification
Freedom from Major Adverse Events (MAEs)
Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve
Time frame: 30 Days
Procedural Success
Defined as residual diameter stenosis ≤50% at the end of the procedure as determined by angiographic core lab
Time frame: At completion of the procedure
Target lesion patency, 30 days
Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram
Time frame: 30 days
Target lesion patency, 6 months
Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram
Time frame: 6 months
Target lesion patency, 12 months
Defined as freedom from CD-TLR and freedom from ≥50% restenosis as determined by duplex ultrasound (DUS) or angiogram
Time frame: 12 months
Clinically-driven target lesion revascularization
Defined as repeat revascularization procedure of the target lesion if PSVR is ≥2.5 by DUS or if angiography shows a percent diameter stenosis \>50% and there are worsening clinical symptoms, worsening Rutherford Clinical Category or ABI that is clearly referable to the target lesion.
Time frame: Through 12 months
Technical success
Defined as the ability to deliver the Thor system and achieve residual diameter stenosis ≤50% after treatment with Thor and prior to adjunctive PTA, as confirmed by independent core laboratory assessments of angiographic images
Time frame: Peri-procedural
Frequency of peri-procedural adverse events
Defined as frequency of adverse events related to the investigational device (Thor system)
Time frame: Within 24 hours of the procedure
Adjunctive devices used with the Thor system
Defined as the use of other devices including angioplasty balloons, drug coated balloons, bailout stents, embolic filters
Time frame: Peri-procedural
Target Limb Ankle-Brachial Index (ABI) change, Discharge
Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at discharge compared to the baseline (Screening) value
Time frame: Discharge or up to 24 hours after the procedure
Target Limb Ankle-Brachial Index (ABI) change, 30 days
Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 30 days compared to the baseline (Screening) value
Time frame: 30 days
Target Limb Ankle-Brachial Index (ABI) change, 6 months
Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 6 months compared to the baseline (Screening) value
Time frame: 6 months
Target Limb Ankle-Brachial Index (ABI) change, 12 months
Defined as the change in blood pressure in the upper limb (arm) and lower limb (leg or toes) at 12 months compared to the baseline (Screening) value
Time frame: 12 months
Rutherford Classification change, 30 days
Defined as the change in Rutherford classification at 30 days compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.
Time frame: 30 days
Rutherford Classification change, 6 months
Defined as the change in Rutherford classification at 6 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.
Time frame: 6 months
Rutherford Classification change, 12 months
Defined as the change in Rutherford classification at 12 months compared to the baseline (Screening) value. Rutherford Classification is a staging system to describe reduced blood flow in the lower limb. Rutherford Classifications values range from the least severe (asymptomatic) which is scored a 0 to the most severe (ulceration or gangrene) which is scored a 6.
Time frame: 12 months
Freedom from Major Adverse Events (MAEs)
Defined as freedom from MAEs including all-cause mortality, clinically driven target lesion revascularization (CD-TLR), unplanned target limb major amputation, and perforations, flow-limiting dissections, and symptomatic distal embolizations that require an intervention to resolve
Time frame: Through 12 months
Change in Short Form Health Survey (SF-36) score, 30 days
Defined as the change in SF-36 score at 30 days compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 30 days
Change in Short Form Health Survey (SF-36) score, 6 months
Defined as the change in SF-36 score at 6 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 6 months
Change in Short Form Health Survey (SF-36) score, 12 months
Defined as the change in SF-36 score at 12 months compared to the baseline (Screening) value. The SF-36 is a patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 12 months
Change in Walking Impairment Questionnaire (WIQ) score, 30 days
Defined as the change in WIQ score at 30 days compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.
Time frame: 30 days
Change in Walking Impairment Questionnaire (WIQ) score, 6 months
Defined as the change in WIQ score at 6 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.
Time frame: 6 months
Change in Walking Impairment Questionnaire (WIQ) score, 12 months
Defined as the change in WIQ score at 12 months compared to the baseline (Screening) value. The WIQ measures self-reported walking impairment, walking distance, walking speed, and stair-climbing ability. In the WIQ there are 21 questions to rate the degree of difficulty with the walking and stair climbing elements. The response for each question is on a 0 to 4 scale, where 0 represents the inability to walk or climb stairs, and 4 represents no difficulty.
Time frame: 12 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 26 months is close to that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Philips Clinical & Medical Affairs Global →